Immunovant Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Selling, General & Admin	79.15	77.24	57.28	48.02	54.23	39.51
Research & Development	408.02	360.92	212.93	160.26	101.81	68.6
Operating Expenses	487.17	438.15	270.21	208.28	156.03	108.12
Operating Income	-487.17	-438.15	-270.21	-208.28	-156.03	-108.12
Interest & Investment Income	24.16	24.73	24.95	7.58	-	-
Other Non Operating Income (Expenses)	2.45	0.47	-1.01	-0.25	-0.78	0.33
EBT Excluding Unusual Items	-460.56	-412.95	-246.27	-200.95	-156.81	-107.79
Pretax Income	-460.56	-412.95	-258.77	-210.95	-156.81	-107.79
Income Tax Expense	3.64	0.89	0.57	0.01	-0.08	-0.36
Net Income	-464.2	-413.84	-259.34	-210.96	-156.73	-107.43
Net Income to Common	-464.2	-413.84	-259.34	-210.96	-156.73	-107.43
Shares Outstanding (Basic)	173	152	138	123	110	88
Shares Outstanding (Diluted)	173	152	138	123	110	88
Shares Change (YoY)	18.37%	9.76%	12.21%	12.21%	24.98%	103.14%
EPS (Basic)	-2.68	-2.73	-1.88	-1.71	-1.43	-1.22
EPS (Diluted)	-2.68	-2.73	-1.88	-1.71	-1.43	-1.22
Free Cash Flow	-423.09	-376.63	-214.59	-188.39	-106.37	-83.54
Free Cash Flow Per Share	-2.44	-2.48	-1.55	-1.53	-0.97	-0.95
EBITDA	-486.75	-437.78	-269.98	-208.08	-155.91	-108.05
D&A For EBITDA	0.42	0.38	0.23	0.19	0.13	0.07
EBIT	-487.17	-438.15	-270.21	-208.28	-156.03	-108.12

Updated Feb 6, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q